Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study

Saša Petar Grgov; Tomislav Tasić; Biljana Radovanović Dinić; Daniela Benedeto Stojanov

doi:10.2298/VSP150415127G

Saša Petar Grgov Department of Gastroenterology and Hepatology, General Hospital Leskovac, Leskovac, Serbia
Tomislav Tasić Department of Gastroenterology and Hepatology, General Hospital Leskovac, Leskovac, Serbia
Biljana Radovanović Dinić Clinic for Gastroenterology and Hepatology, Clinical Center Niš, Niš, Serbia
Daniela Benedeto Stojanov Clinic for Gastroenterology and Hepatology, Clinical Center Niš, Niš, Serbia

DOI: https://doi.org/10.2298/VSP150415127G

Keywords: helicobacter pylori, helicobacter infection, disease eradication, clinical protocols, probiotics, treatment outcome,

Abstract

Background/Aim. Some studies suggest the benefit of applying different probiotic strains in combination with antibiotics in the eradication of Helicobacter pylori (H. pylori) infection. The aim of this study was to evaluate the effect of co-administration of multiple probiotic strains with triple H. pylori eradication therapy. Methods. This prospective study included 167 patients with dyspeptic symptoms and chronic gastritis who were diagnosed with H. pylori infection and randomized into two groups. The group I of 77 patients underwent triple eradication therapy, for 7 days, with lansoprazole, 2 × 30 mg half an hour before the meal, amoxicillin 2 × 1.000 mg per 12 hours and clarithromycin 2 × 500 mg per 12 hours. After the 7th day of the therapy, lansoprazole continued at a dose of 30 mg for half an hour before breakfast for 4 weeks. The group II of 90 patients received the same treatment as the patients of the group I, with the addition of the probiotic cultures in the form of a capsule comprising Lactobacillus Rosell-52, Lactobacillus Rosell-11, Bifidobacterium Rosell-1755 and Saccharomyces boulardii, since the beginning of eradication for 4 weeks. Eradication of H. pylori infection control was performed 8 weeks after the therapy by rapid urease test and histopathologic evaluation of endoscopic biopsies or by stool antigen test for H. pylori. Results. Eradication of H. pylori infection was achieved in 93.3% of the patients who received probiotics with eradication therapy and in 81.8% of patients who were only on eradication therapy without probiotics. The difference in eradication success was statistically significant, (p < 0.05). The incidence of adverse effects of eradication therapy was higher in the group of patients who were not on probiotic (28.6%) than in the group that received probiotic (17.7%), but the difference was not statistically significant. Conclusion. Multiple probiotic strains addition to triple eradication therapy of H. pylori achieves a significantly better eradication success, with fewer side effects of antibiotics

Author Biographies

Saša Petar Grgov, Department of Gastroenterology and Hepatology, General Hospital Leskovac, Leskovac, Serbia

Head of Department of internal medicine

Tomislav Tasić, Department of Gastroenterology and Hepatology, General Hospital Leskovac, Leskovac, Serbia

clinical doctor

Biljana Radovanović Dinić, Clinic for Gastroenterology and Hepatology, Clinical Center Niš, Niš, Serbia

profesor of faculty

Daniela Benedeto Stojanov, Clinic for Gastroenterology and Hepatology, Clinical Center Niš, Niš, Serbia

docent of faculty

References

Patel A, Shar N, Prajapati JB. Clinical application of probiotics in the treatment of Helicobacter pylori infection: A breaf re-view J Microbiol Immunol Infect 2014; 47(5): 429−37.

Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of He-licobacter pylori infection: meeting the challenge of antimi-crobial resistance. World J Gastroenterol 2014; 20(29): 9898−911.

Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin. Cancer Biol. 2013; 23(6 Pt B): 492−501.

Malfertheiner P, Megraud F, O'morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61(5): 646−64.

O'Connor A, Vaira D, Gisbert JP, O'Morain C. Treatment of He-licobacter pylori infection 2014. Helicobacter 2014; 19(Suppl 1): 38−45.

Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori?, A systematic review and meta-analysis. Scand J Gastroenterol 2014; 49(5): 528−38.

Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, et al. Sitafloxacin-based third-line rescue regimens for He-licobacter pylori infection in Japan. J Gastroenterol Hepatol 2014; 29(3): 487−93.

Praitano MM, Iacono S, Francavilla R. Probiotics and Helicobacter pylori infection. Med Universit 2012;14:217-223.

Zheng PX, Fang HY, Yang HB, Tien NY, Wang MC, Wu JJ. Lactobacillus pentosus strain LPS16 produces lactic acid, inhibiting multidrug-resistant Helicobacter pylori. J Microbiol Immunol Infect 2014; pii: S1684-1182(14)00079-6. (In Press)

Saxelin M, Tynkkynen S, Mattila-Sandholm T, Vos WM. Probiotic and other functional microbes: from markets to mechanisms. Curr Opin Biotechnol 2005; 16(2): 204−11.

Du YQ, Su T, Fan JG, Lu YX, Zheng P, Li XH, et al. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012; 18(43): 6302−7.

Efrati C, Nicolini G, Cannaviello C, Sed NP, Valabrega S. Helico-bacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation. World J Gastroenterol 2012; 18(43): 6250−4.

Manfredi M, Bizzarri B, Sacchero RI, Maccari S, Calabrese L, Fabbian F, et al. Helicobacter pylori infection in clinical practice: Probiotics and a combination of probiotics + lactoferrin im-prove compliance, but not eradication, in sequential therapy. Helicobacter 2012; 17(4): 254−63.

Shavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Kho-dadoostan M, et al. The effects of multistrain probiotic com-pound on bismuth-containing quadruple therapy for Helico-bacter pylori infection: A randomized placebo-controlled triple-blind study. Helicobacter 2013; 18(4): 280−4.

Collado MC, González A, González R, Hernández M, Ferrús MA, Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori. Int J Antimicrob Agents 2005; 25(5): 385−91.

Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007; 137(3 Suppl 2): 812S−8S.

Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Va-paatalo H, et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005; 21(10): 1263−72.

Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F, Pola P, et al. A lyophilized and inactivated culture of Lactoba-cillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000; 14(12): 1625−9.

Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS, et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16(9): 1669−75.

Zhu R, Chen K, Zheng Y, Zhang H, Wang J, Xia Y, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol 2014; 20(47): 18013−21.

Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis. Am J Gastroenterol 2006; 101(7): 1467−75.

Hammerman C, Bin-Nun A, Kaplan M. Safety of probiotics: comparison of two popular strains. BMJ 2006; 333(7576): 1006−8.

Boyle RJ, Roy MR, Tang ML. Probiotic use in clinical practice: what are the risks. Am J Clin Nutr 2006; 83: 1256−64.

Mäkeläinen H, Tahvonen R, Salminen S, Ouwehand AC. In vivo safety assessment of two Bifidobacterium longum strains. Mi-crobiol Immunol 2003; 47(12): 911−4.